Increased risk weighs on SH FOSUN PHARMA, penalising its rating down to Neutral
The independent financial analyst theScreener just lowered the general evaluation of SH FOSUN PHARMA (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as moderately risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Neutral. As of the analysis date February 19, 2021, the closing price was CNY 47.72 and its target price was estimated at CNY 36.35.Shanghai Fosun Pharmaceutical (Group) is principally engaged in the manufacture and sale of medical diagnostic products, pharmaceuticals and medical devices. In addition, Co. is engaged in the provision of advisory services; manufacture of electronic products, computers and industrial chemicals; and import and export of auxiliary materials, machinery equipment, instrument measuring appliances, spare parts and related technology in the production and research process. Through its subsidiaries, Co. is also engaged in research and development of health care products; the integration of computer network systems, and industry investment and management.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.